Beijing Science Sun Pharmaceutical Co., Ltd. (300485) Stock Recommendation | Score, Valuation, Technicals & Financial Trend

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.Unlock 29 Markets

Comparison

Company

Score

Quality

Valuation

Financial

Technical

Beijing Science Sun Pharmaceutical Co., Ltd.

Why is Beijing Science Sun Pharmaceutical Co., Ltd. ?

Poor Management Efficiency with a low ROCE of 2.69%

The company has been able to generate a Return on Capital Employed (avg) of 2.69% signifying low profitability per unit of total capital (equity and debt)

Poor long term growth as Net Sales has grown by an annual rate of -19.18% and Operating profit at -31.17% over the last 5 years

Flat results in Mar 25

PRE-TAX PROFIT(Q) Lowest at CNY 1.25 MM
NET SALES(Q) At CNY 91.25 MM has Fallen at -10.86%
OPERATING PROFIT(Q) Lowest at CNY 0.52 MM

With ROE of 0.75%, it has a fair valuation with a 0.86 Price to Book Value

Over the past year, while the stock has generated a return of 50.25%, its profits have risen by 126.8% ; the PEG ratio of the company is 0.9

Market Beating Performance

The stock has generated a return of 50.25% in the last 1 year, much higher than market (China Shanghai Composite) returns of 15.18%

Real-Time Research Report

Verdict Report

How much should you hold?

Overall Portfolio exposure to Beijing Science Sun Pharmaceutical Co., Ltd. should be less than 10%
Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock

Is Beijing Science Sun Pharmaceutical Co., Ltd. for you?

High Risk, High Return

Absolute

Risk Adjusted

Volatility

Beijing Science Sun Pharmaceutical Co., Ltd.

38.45%

1.38

63.26%

China Shanghai Composite

14.77%

1.01

15.10%

Quality

Management Risk

Growth

Capital Structure

Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor

Value

Sales Growth (5y)

-19.18%

EBIT Growth (5y)

-31.17%

EBIT to Interest (avg)

40.84

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-0.47

Sales to Capital Employed (avg)

0.14

Tax Ratio

23.40%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

ROCE (avg)

2.69%

ROE (avg)

3.20%

Valuation

Valuation Scorecard

Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors

Factor

Value

P/E Ratio

115

Industry P/E

Price to Book Value

0.86

EV to EBIT

74.28

EV to EBITDA

20.22

EV to Capital Employed

0.73

EV to Sales

3.33

PEG Ratio

0.91

Dividend Yield

ROCE (Latest)

0.98%

ROE (Latest)

0.75%

Technicals

Technical key factors

Indicator

Weekly

Monthly

MACD

Mildly Bearish

Bullish

RSI

No Signal

Bollinger Bands

Bearish

Mildly Bullish

Moving Averages

Mildly Bullish (Daily)

KST

Bearish

Bullish

Dow Theory

No Trend

OBV

No Trend

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Technical Movement

Analyse All Technical Factors

Financial Trend

Financial Trend Scorecard

Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

18What is working for the Company

NET PROFIT(Q)

At CNY 17.81 MM has Grown at 664.48%

ROCE(HY)

Highest at 4.87%

RAW MATERIAL COST(Y)

Fallen by 0.98% (YoY

CASH AND EQV(HY)

Highest at CNY 3,176.67 MM

DEBT-EQUITY RATIO (HY)

Lowest at -47.25 %

DEBTORS TURNOVER RATIO(HY)

Highest at 7.76%

-8What is not working for the Company

PRE-TAX PROFIT(Q)

Lowest at CNY 1.25 MM

NET SALES(Q)

At CNY 91.25 MM has Fallen at -10.86%

OPERATING PROFIT(Q)

Lowest at CNY 0.52 MM

OPERATING PROFIT MARGIN(Q)

Lowest at 0.57 %

Here's what is working for Beijing Science Sun Pharmaceutical Co., Ltd.

Net Profit

At CNY 17.81 MM has Grown at 664.48%

over average net sales of the previous four periods of CNY 2.33 MM

MOJO Watch

Near term Net Profit trend is very positive

Net Profit (CNY MM)

Cash and Eqv

Highest at CNY 3,176.67 MM

in the last six Semi-Annual periods

MOJO Watch

Short Term liquidity is improving

Cash and Cash Equivalents

Debt-Equity Ratio

Lowest at -47.25 %

in the last five Semi-Annual periods

MOJO Watch

The company has been reducing its borrowing as compared to equity capital

Debt-Equity Ratio

Debtors Turnover Ratio

Highest at 7.76%

in the last five Semi-Annual periods

MOJO Watch

Company has been able to sell its Debtors faster

Debtors Turnover Ratio

Raw Material Cost

Fallen by 0.98% (YoY)

MOJO Watch

The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin

Raw Material Cost as a percentage of Sales

Here's what is not working for Beijing Science Sun Pharmaceutical Co., Ltd.

Pre-Tax Profit

At CNY 1.25 MM has Fallen at -86.98%

over average net sales of the previous four periods of CNY 9.62 MM

MOJO Watch

Near term Pre-Tax Profit trend is very negative

Pre-Tax Profit (CNY MM)

Pre-Tax Profit

Lowest at CNY 1.25 MM and Fallen

In each period in the last five periods

MOJO Watch

Near term Pre-Tax Profit trend is very negative

Pre-Tax Profit (CNY MM)

Net Sales

At CNY 91.25 MM has Fallen at -10.86%

over average net sales of the previous four periods of CNY 102.37 MM

MOJO Watch

Near term sales trend is negative

Net Sales (CNY MM)

Operating Profit

Lowest at CNY 0.52 MM

in the last five periods

MOJO Watch

Near term Operating Profit trend is negative

Operating Profit (CNY MM)

Operating Profit Margin

Lowest at 0.57 %

in the last five periods

MOJO Watch

Company's profit margin has deteriorated

Operating Profit to Sales